High tacrolimus intra-patient variability is associated with graft rejection, and de novo donor-specific antibodies occurrence after liver transplantation

Table 2 Risk factors for a graft-rejection episode

Variable	Univariate analyses			Multivariate analyses
	OR	95%CI	P value	OR	95%CI	P value
MELD score > 30 (n = 31)	0.55	0.12-1.90	0.42	-
Initial liver disease
(1) Alcohol cirrhosis (n = 49) vs (2, 3, 4)	0.58	0.18-1.68	0.34	-
(2) Viral disease (n = 36) vs (1, 3, 4)	1.34	0.44-3.90	0.61	-
(3) Auto-immune ILD (n = 13) vs (1, 2,4)	3.12	0.71-12.47	0.07	1.00	0.51-1.15	0.210
(4) Other (n = 18) vs (1, 2, 3)	0.49	0.05-2.37	0.52	-
Induction therapy, yes (n = 87)	0.66	0.22-2.15	0.42	-
Polyclonal antibodies (vs other)	3.89	0.70-20.13	0.06	2.87	0.61-13.47	0.180
IL2R blockers (vs other)	0.40	0.14-1.70	0.08	0.52	0.185-1.50	0.230
Donors’ age > 50 yr (n = 69)	0.98	0.35-2.88	1.00	-
Recipients’ age > 50 yr (n = 92)	0.61	0.20-2.01	0.41	-
HCV-RNA + At transplantation (n = 21)	1.96	0.54-6.45	0.22	-
Steroid withdrawal during the FU (n = 19)	2.30	0.63-7.82	0.20	-
De novo DSAs during the FU (n = 13)	2.80	0.64-11.19	0.13	-
Tacrolimus trough level < 5 ng/mL (n = 34)	3.00	1.05-8.96	0.02	3.68	1.30-10.41	0.014
CV-IPV tacrolimus (continuous variable)	2.70	1.88-13.45	0.01	1.10	1.01-1.11	0.008
CV-IPV > 35%	3.05	1.05-8.96	0.03	3.07	1.14-8.24	0.030
CV-IPV > 0%	2.97	0.91-9.30	0.04	4.16	1.38-12.50	0.010
CV-C0/d-IPV	1.89	0.67-5.74	0.24	-

FU: Follow-up; ILD: Initial liver disease; HCV: Hepatitis C virus; CV-IPV: Coefficient of variability-intra-patient variability; CV-C₀/d-IPV: Coefficient of variability corrected for the corresponding daily dose-intra-patient variability.